Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrukinzumab in active ulcerative colitis
NL-OMON35786Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anrukinzumab in autoimmune colitis (4 arms), sponsored by Pfizer. Primary endpoint: Fold change from baseline in fecal calprotectin at Week 14. Planned start Aug 2011; status: not yet recruiting.
02
Drugs
anrukinzumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON35786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35786.